At present, due to increased costs, decreased productivity, and lack of breakthrough technologies, many pharmaceutical firms face various challenges in their research and development projects. A variety of environmental concerns have also been gradually placing pressure on the pharmaceutical industry, including substantial profit losses due to patent expiration, more expensive health care facilities, and more stringent regulatory requirements. A system-oriented approach to finding innovative solutions is essential to this complicated problem. In our opinion, the key to solving these challenges is to increase the quality and number of creative and cost-effective new pharmaceutical products without incurring excessive R&D expenses, both for the future profitability of pharmaceutical industries and developments in healthcare. Our main emphasis is to highlight the strategies and models like Quality by Design, Lean Six Sigma, Organ-on-Chip, Chorus, AI, and so on in delivering innovations, which can be a good positive change for industries as to increase productivity in terms of time efficiency and innovation as well. These models focus on the creation and diffusion of knowledge internal to the firms. The major focus points should include critical investigation in innovations where the risk is high, as this can lead to the safer side of the development. We then propose specific strategies that could have the most substantial impact on improving R&D productivity. Besides this, the selection of strategy and models at the same point is as important as its implementation and its accurate selection can assist pharmaceutical companies to improve R&D organizations and their productivity.

目前，由于成本增加，生产率下降和缺乏突破性技术，许多制药公司在研发项目中面临各种挑战。各种环境问题也逐渐对制药业造成压力，包括由于专利到期，更昂贵的医疗设施以及更严格的监管要求而造成的巨额利润损失。对于这个复杂的问题，寻找创新解决方案的面向系统的方法至关重要。我们认为，解决这些挑战的关键是提高创新性和成本效益的新药品的质量和数量，而不会产生过多的研发费用，无论是为了制药行业的未来盈利能力还是医疗保健领域的发展。我们的主要重点是突出战略和模型，例如质量设计，精益六西格码，芯片上的器官，合唱，人工智能等，以提供创新，这对于提高生产率的行业来说可能是一个很好的积极变化。时间效率和创新方面也是如此。这些模型着重于企业内部知识的创造和传播。主要重点应包括对风险较高的创新进行批判性调查，因为这可能导致开发更安全。然后，我们提出可能对提高研发生产率产生最大影响的具体策略。除此之外，在同一点选择策略和模型与其实施同样重要，准确选择可以帮助制药公司改善R＆R。